I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 0.9397 USD -2.01% Market Closed
Market Cap: 76m USD
Have any thoughts about
I-Mab?
Write Note

I-Mab
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

I-Mab
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
I-Mab
NASDAQ:IMAB
Operating Income
-ÂĄ1.2B
CAGR 3-Years
N/A
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ8.8B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Operating Income
ÂĄ2.3B
CAGR 3-Years
31%
CAGR 5-Years
46%
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
ÂĄ7B
CAGR 3-Years
-7%
CAGR 5-Years
25%
CAGR 10-Years
50%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Income
ÂĄ2.1B
CAGR 3-Years
64%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

I-Mab
Glance View

Market Cap
76m USD
Industry
Biotechnology

I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.

IMAB Intrinsic Value
0.7454 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is I-Mab's Operating Income?
Operating Income
-1.2B CNY

Based on the financial report for Dec 31, 2023, I-Mab's Operating Income amounts to -1.2B CNY.

What is I-Mab's Operating Income growth rate?
Operating Income CAGR 5Y
-23%

Over the last year, the Operating Income growth was 37%.

Back to Top